NYC Healthcare News



CAMD releases first combined clinical trial data on neuro-degenerative diseases

September 30, 2015

Roughly 6.5 million people in the U.S. are afflicted with Alzheimer's and Parkinson's diseases, with costs reaching as much as $175 billion annually. Worldwide there are already an estimated 30 million people with dementia alone.  By 2050, the number will rise to over 100 million. Halting or slowing the progression of these diseases will prevent untold suffering and save tens of billions of dollars every year.

"Data sharing is the backbone of several CAMD projects designed to identify patients who might develop brain diseases, i.e., before symptoms are apparent," said Marc Cantillon, MD, Director of C-Path's Coalition Against Major Diseases.  "Our goal is to develop tools to prevent or slow these diseases so patients can maintain independence and quality of life."

The CAMD database will allow researchers to design more efficient clinical trials that have the maximum chance of demonstrating if a new treatment is truly safe and effective.  In addition, the coalition is identifying biomarkers that identify patients in the very early stages of Alzheimer's disease and Parkinson's disease.

According to Maria Isaac, MASc, MD, PhD, Scientific Administrator, Scientific Advice, Human Medicines Special Areas Sector of the European Medicines Agency (EMA), "Within the context of the Innovative Medicines Initiative (IMI) in Europe, the EMA is committed to similar goals as C-Path's consortia, i.e., to help biopharmaceutical drug development, for the benefits of patients.  The Agency is especially interested in reviewing CAMD's Alzheimer's biomarkers and disease progression models."

Frank Casty, MD, VP Technical Evaluations, AstraZeneca Pharmaceuticals LP, and Co-Director of CAMD said, "AstraZeneca strongly believes that a healthier world must come from collaboration, in making better, deeper connections with all our stakeholders, and sharing skills and ideas to meet a common goal ?? improved health."

SOURCE Coalition Against Major Diseases